Dompé has launched REP0112, a Phase II/III trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation, a procedure where pancreatic cells are taken from the patient’s own pancreas and surgically removed for a pancreatic pathology. Enrollment of the first patient is scheduled by the end of 2013 and results are expected in early 2016. REP0112 will enroll 100 islet transplantation-naïve adult patients with iatrogenic diabetes who have undergone total pancre...